Palatin is focused on developing therapeutics that leverage the melanocortin system to address conditions such as hypoactive sexual desire disorder (HSDD) and harmful inflammation. They have obtained FDA approval for Vyleesi, a treatment for HSDD, and are now working on therapeutics for eye, gastrointestinal, and kidney diseases. Their most advanced product, PL9643, is a topical treatment for dry eye disease, and they have other therapies in development for ophthalmic indications. Palatin also plans to conduct clinical studies for ulcerative colitis and kidney disease.